Development of High Throughput Assays for HVA CA Channels

HVA CA 通道高通量检测的开发

• 批准号: 7049771
• 负责人: EDWARD PEREZ-REYES
• 金额: $ 17.11万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-01-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7049771
• 关键词: afferent nerve; analgesics; binding sites; biotechnology; calcium channel; calcium channel blockers; calcium flux; cell line; chronic pain; conotoxin; dihydropyridines; drug screening /evaluation; fluorescent dye /probe; fluorimetry; high throughput technology; neuropharmacology; protein structure function; recombinant proteins; sensory neuropathy; small molecule; spinal ganglion; technology /technique development; transfection /expression vector; voltage /patch clamp; voltage gated channel

DESCRIPTION (provided by applicant): Voltage-gated calcium channels are an established drug target. Nevertheless, therapeutically useful drugs only target one of the ten members of the Ca2+ channel family, the cardiovascular L-type channel (Cav1.2). Considerable evidence supports the hypothesis that a small molecule blocker of N-type channels (Cav2.2) would be effective in the treatment of chronic pain. N-type channels in sensory neurons mediate calcium influx into presynaptic terminals, thereby triggering neurotransmitter release onto neurons in the dorsal horn of the spinal cord. Knock-out of the gene encoding the a1 subunits of N-type channels (?12.2) diminishes pain sensitivity and reduces the development of neuropathic pain symptoms after spinal nerve ligation. Finally, ziconotide, a peptide toxin that is highly selective for N-type channels, demonstrated safety and efficacy in clinical trials for the treatment of intractable pain in cancer and AIDS patients after intrathecal infusion. These studies establish the proof-of-concept that an orally available small molecule blocker of N-type channels would be a major therapeutic advance for chronic pain. Two major obstacles have hampered the development of such drugs: one, N-type channels mediate neurotransmitter release at many synapses, so a blocker might have many side effects; and two, the lack of a high throughput assay to screen candidate compounds. Recent studies demonstrate that nociceptive neurons express a specific splice variant isoform of ?12.2. Therefore, a selective and state-dependent blocker of this isoform might produce analgesia without side effects. The goal of this grant is to develop stable cell lines of recombinant N-type channels that will be useful in high throughput screening. The cell lines will be tested for channel expression using whole cell clamp electrophysiology, and their usefulness in a screen will be tested using a fluorescent dye assay to measure calcium influx. A final goal is to test whether the N-type channel variants have unique pharmacological profiles. Chronic pain continues to be a major public health problem, affecting 40 million Americans, with little relief from current drugs. By targeting an important protein in the pain pathway, the research funded by this grant will provide tools that can be used to screen candidate compounds during the development of novel analgesics.

描述(由申请人提供)： 电压门控钙通道是一个既定的药物靶点。然而，治疗上有用的药物只针对钙离子通道家族十个成员中的一个，即心血管L型通道(CAV1.2)。相当多的证据支持这样的假设，即N型通道的小分子阻滞剂(Cav2.2)在治疗慢性疼痛方面是有效的。感觉神经元中的N型通道介导钙离子内流到突触前终末，从而触发神经递质释放到脊髓背角的神经元。敲除编码N型通道A1亚基的基因(？12.2)可降低疼痛敏感性，并减少脊神经结扎后神经病理性疼痛症状的发展。最后，一种对N型通道具有高度选择性的多肽毒素齐康肽，在鞘内注射后治疗癌症和艾滋病患者的顽固性疼痛的临床试验中证明了安全性和有效性。这些研究证实，口服N型通道的小分子阻滞剂将是慢性疼痛的主要治疗进步。两个主要障碍阻碍了这类药物的开发：第一，N型通道介导许多突触的神经递质释放，因此阻滞剂可能有许多副作用；第二，缺乏高通量分析来筛选候选化合物。最近的研究表明，伤害性神经元表达一种特异的剪接异构体？12.2。因此，这种异构体的选择性和状态依赖的阻断剂可能产生无副作用的止痛。这笔赠款的目标是发展稳定的重组N型通道细胞系，这将有助于高通量筛选。这些细胞系将使用全细胞钳电生理学来测试通道表达，并将使用荧光染料试验来测试它们在筛查中的有用性，以测量钙内流。最终目标是测试N型通道变体是否具有独特的药理学特征。 慢性疼痛仍然是一个主要的公共卫生问题，影响着4000万美国人，目前的药物几乎没有缓解作用。通过瞄准疼痛通路中的一种重要蛋白质，这项由这笔拨款资助的研究将提供工具，可用于在新型止痛药的开发过程中筛选候选化合物。